In 2016, immunotherapy, with Programmed Death- 1/Programmed Death ligand-1 (PD-1/PD-L1) inhibitors was first introduced for metastatic (stage IV) NSCLC patients with PD-L1 positive tumors in second-line (2L). This evidence concerns the gene CD274 and non-small cell lung carcinoma.